These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 24721323

  • 1. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, Nie LP, Wan J, Lu XP, Zhang W, Ning ZQ.
    Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
    [Abstract] [Full Text] [Related]

  • 2. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
    Zhang BY, Wang YM, Gong H, Zhao H, Lv XY, Yuan GH, Han SR.
    Int J Clin Exp Pathol; 2015 May; 8(1):25-37. PubMed ID: 25755690
    [Abstract] [Full Text] [Related]

  • 3. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y, Wang Y, Zhou Y, Li J, Chen K, Zhang L, Deng M, Deng S, Li P, Xu B.
    Clin Epigenetics; 2017 May; 9():83. PubMed ID: 28814980
    [Abstract] [Full Text] [Related]

  • 4. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N, Sun P, Jin H, Yang Y, Zhao Q, Zhou L, Guo L, Yang X, Lu L.
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of cytotoxic effect of the combination of a pyridinyl carboxamide derivative and oxaliplatin on NCI-H1299 human non-small cell lung carcinoma cells.
    Teixeira SF, de Azevedo RA, Silva AC, Braga RC, Jorge SD, Barbuto JAM, Andrade CH, Ferreira AK.
    Biomed Pharmacother; 2016 Dec; 84():1019-1028. PubMed ID: 27768927
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S, Nan P, Li C, Lin F, Li H, Wang T, Zhou C, Zhang X, Meng X, Qian H, Wang H, Dong M.
    Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
    [Abstract] [Full Text] [Related]

  • 7. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L, Qiu S, Liu Y, Liu Z, Zheng Y, Su X, Chen B, Chen H.
    Neoplasma; 2016 Mar; 63(2):193-200. PubMed ID: 26774139
    [Abstract] [Full Text] [Related]

  • 8. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
    Gavrilov V, Lavrenkov K, Ariad S, Shany S.
    Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
    [Abstract] [Full Text] [Related]

  • 9. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
    Azijli K, van Roosmalen IA, Smit J, Pillai S, Fukushima M, de Jong S, Peters GJ, Bijnsdorp IV, Kruyt FA.
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1273-83. PubMed ID: 24744163
    [Abstract] [Full Text] [Related]

  • 10. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y, Zhang XL, Liu ZX, Zhao JJ, Pan QZ, Wen XZ, Xiao W, Xu BS, Hong DC, Guo TH, Shen LJ, Fan WJ, Chen HY, Weng DS, Xu HR, Zhou PH, Zhang YZ, Niu XH, Zhang X.
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [Abstract] [Full Text] [Related]

  • 11. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.
    Rossi A, Di Maio M.
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):653-60. PubMed ID: 27010977
    [Abstract] [Full Text] [Related]

  • 12. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
    Wu YF, Ou CC, Chien PJ, Chang HY, Ko JL, Wang BY.
    Phytomedicine; 2019 Mar 15; 56():94-102. PubMed ID: 30668358
    [Abstract] [Full Text] [Related]

  • 13. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC, Peng RW, Dorn P, Froment L, Schmid RA, Marti TM.
    BMC Cancer; 2016 Feb 19; 16():125. PubMed ID: 26895954
    [Abstract] [Full Text] [Related]

  • 14. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT, Li WC, Gao S, Wang F, Li XQ, Yu HQ, Fan LL, Wei W, Wang H, Sun GP.
    Clin Lung Cancer; 2015 Sep 19; 16(5):e55-66. PubMed ID: 25979647
    [Abstract] [Full Text] [Related]

  • 15. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
    Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH.
    Cancer Chemother Pharmacol; 2003 Apr 19; 51(4):337-48. PubMed ID: 12721762
    [Abstract] [Full Text] [Related]

  • 16. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K, Fang W, Chen Y, Lin S, Chen X.
    Oncol Rep; 2014 Sep 19; 32(3):1234-42. PubMed ID: 25017445
    [Abstract] [Full Text] [Related]

  • 17. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T, Okamoto I, Takezawa K, Yamanaka K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada Y, Kuwata K, Fukuoka M, Nakagawa K.
    Br J Cancer; 2010 Jun 29; 103(1):36-42. PubMed ID: 20517311
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY, Xu YP, Jin W, Lou LG.
    Anticancer Drugs; 2012 Aug 29; 23(7):698-705. PubMed ID: 22441567
    [Abstract] [Full Text] [Related]

  • 19. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 29; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 20. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z, Zeng Q, Zhang B, Liu H, Wang W.
    Biochimie; 2014 Dec 29; 107 Pt B():257-62. PubMed ID: 25220870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.